<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987035</url>
  </required_header>
  <id_info>
    <org_study_id>FCRE-200504</org_study_id>
    <nct_id>NCT03987035</nct_id>
  </id_info>
  <brief_title>BGP Stent as Bridging Stent in FEVAR</brief_title>
  <official_title>Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System as Bridging Stent in FEVAR for Complex Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Giovanni Torsello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FCRE (Foundation for Cardiovascular Research and Education)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to evaluate, in a controlled setting, the&#xD;
      safety and performance of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft&#xD;
      System (Bentley InnoMed, Hechingen, Germany) implanted as bridging stent in FEVAR&#xD;
      (fenestrated endovascular aortic repair) for complex aortic aneurysms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Application of BeGraft Peripheral Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy endpoint (1) - Technical success</measure>
    <time_frame>1 day post-op</time_frame>
    <description>Successful introduction and deployment of the BeGraft Peripheral (BGP) balloon expandable covered stent Graft System (Bentley Innomed, Hechingen, Germany) implanted as bridging stent in FEVAR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy endpoint (2) ) Bridging stent patency at 12 months</measure>
    <time_frame>12 months post-op</time_frame>
    <description>defined as absence of restenosis (≥50% stenosis) or sole target vessel occlusion based on CT Angio at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety endpoint at 12 months</measure>
    <time_frame>12 months post-op</time_frame>
    <description>Absence of procedure related complications and bridging stent related endoleaks at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bridging stent patency post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Bridging stent patency post-op and at 6-, 12- and 24-months, defined as absence of restenosis (≥50% stenosis) or sole target vessel occlusion based on Duplex ultrasound or CT Angio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from bridging stent related endoleaks post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Freedom from bridging stent related endoleaks post-op and at 6-, 12- and 24- months, based on imaging (duplex ultrasound, CT angiography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from bridging stent related secondary intervention post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Freedom from bridging stent related secondary intervention post-op, 6-, 12- and 24- months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from type I &amp; III endoleaks post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Freedom from type I &amp; III endoleaks post procedure and at 6, 12 and 24-months, based on imaging (duplex ultrasound, CT angiography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from stent graft migration post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>defined as freedom from stent graft migration (more than 10 mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from AAA diameter increase</measure>
    <time_frame>6-, 12, and 24- months post-op</time_frame>
    <description>defined as more than 5mm increase in maximum diameter measured at 6- , 12- and 24- months as compared to postop-implantation, based on imaging (duplex ultrasound or CT Angiography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from aneurysm related secondary endovascular procedures post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Freedom from aneurysm related secondary endovascular procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from conversion to open surgical repair post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Freedom from conversion to open surgical repair post-op</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from aneurysm related mortality post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Freedom from aneurysm related mortality post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from aneurysm rupture within 12- and 24-months post-implantation</measure>
    <time_frame>12, and 24- months post-op</time_frame>
    <description>Freedom from aneurysm rupture within 12- and 24-months post-implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from any major adverse events post-procedure</measure>
    <time_frame>1 day post-op, 6-, 12, and 24- months post-op</time_frame>
    <description>Freedom from any major adverse events post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life scores</measure>
    <time_frame>12- and 24-months post-op</time_frame>
    <description>Health Related Quality of Life scores at 12- and 24-months post implantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thoracoabdominal Aortic Aneurysm, Without Mention of Rupture</condition>
  <condition>Abdominal Aortic Aneurysm, Without Mention of Rupture</condition>
  <arm_group>
    <arm_group_label>BGP Stent Graft System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGP Stent Graft System as bridging stent in Fenestrated Endovascular Repair (FEVAR) for complex aortic aneurysms</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BeGraft Peripheral (BGP) Stent Graft System as bridging stent</intervention_name>
    <description>BGP Stent Graft System as bridging stent</description>
    <arm_group_label>BGP Stent Graft System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient eligible for elective repair of AAA/TAAA extent IV with FEVAR in accordance&#xD;
             with the applicable guidelines for vascular interventions (Aneurysm size 5.5cm or&#xD;
             aneurysm growth of &gt;5 mm within 6 months or 1 cm within 1 year).&#xD;
&#xD;
          -  Patient is willing to comply with specified follow-up evaluations at the specified&#xD;
             times&#xD;
&#xD;
          -  Patient is &gt;55 years old&#xD;
&#xD;
          -  Patient understands the nature of the procedure and provides written informed consent,&#xD;
             prior to enrollment in the study&#xD;
&#xD;
          -  Patient has a projected life-expectancy of at least 12-months&#xD;
&#xD;
          -  Indication of elective repair of AAA or TAAA with FEVAR in accordance with the&#xD;
             applicable guidelines for vascular interventions&#xD;
&#xD;
          -  Patient needs to have a landing zone in their target vessel of at least 10mm&#xD;
&#xD;
          -  No early important division branch from the target vessel with risk of coverage&#xD;
&#xD;
          -  Absence of dissection&#xD;
&#xD;
          -  Target vessels (renal arteries, superior mesenteric artery and celiac trunk) should&#xD;
             have a diameter between 5 and 10 mm&#xD;
&#xD;
          -  Patient eligible for fenestrated endovascular repair as per IFU of the fenestrated&#xD;
             endograft&#xD;
&#xD;
          -  Angulation of the aorta at the level of the target vessels &lt;45 degrees&#xD;
&#xD;
          -  The fenestrated endograft has to be constructed so the fenestrations lie in front of&#xD;
             the orifice of the target vessel, and the gap between the fenestration and the orifice&#xD;
             of the target vessel should not exceed 10mm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously implanted endograft&#xD;
&#xD;
          -  Patients refusing treatment&#xD;
&#xD;
          -  Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are&#xD;
             contraindicated&#xD;
&#xD;
          -  Patients with uncorrected bleeding disorders or heparin induced thrombozytopenia&#xD;
&#xD;
          -  Female patient with child bearing potential not taking adequate contraceptives or&#xD;
             currently breastfeeding&#xD;
&#xD;
          -  Any planned surgical intervention/procedure within 30 days of the study procedure&#xD;
&#xD;
          -  Any patient considered to be hemodynamically unstable at onset of procedure&#xD;
&#xD;
          -  Patient is currently participating in another investigational drug or device study&#xD;
             that has not completed the entire follow up period.&#xD;
&#xD;
          -  Patients with diffuse distal disease resulting in poor stent outflow&#xD;
&#xD;
          -  Fresh thrombus formation&#xD;
&#xD;
          -  Stenosed (&gt;50%) or occluded target vessel&#xD;
&#xD;
          -  Angulation between renal artery and aortic wall &lt;30 degrees&#xD;
&#xD;
          -  Patients with known hypersensitivity to the stent material (L605) and/or PTFE&#xD;
&#xD;
          -  Hybrid Approach&#xD;
&#xD;
          -  Patients with a connective tissue disorder&#xD;
&#xD;
          -  Patients with mycotic or inflammatory aneurysm&#xD;
&#xD;
          -  Myocardial infarction or stroke within 3 months prior to the procedure&#xD;
&#xD;
          -  Patients with an unstable angina pectoris or heart insufficiency NYHA 3 or 4&#xD;
&#xD;
          -  Patients with ASA classification 5 or higher&#xD;
&#xD;
          -  Contraindications against contrast enhanced angiography (a.e. massive hyperthyroidism)&#xD;
&#xD;
          -  Patients with increased risk of intraoperative rupture&#xD;
&#xD;
          -  Patients with access vessel which are too tortuous, narrow or any kind of reason that&#xD;
             would lead to failure of introducing and advancing an introducer sheath&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Foundation for Cardiovascular Research and Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annelena Held-Wehmöller</last_name>
    <phone>+4915785128140</phone>
    <email>info@fcre.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drosos Kotelis, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Heart Center Freiburg- Bad Krozingen</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Czerny</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Gießen</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Kalder, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tilo Kölbel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital LMU Munich</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaos Tsilimparis, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital</name>
      <address>
        <city>Münster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Bosiers, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Süd</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Verhoeven, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Regensburg</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyriakos Oikonomou, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Geisbüsch, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 12, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>FCRE (Foundation for Cardiovascular Research and Education)</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Torsello</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

